<DOC>
	<DOCNO>NCT01276015</DOCNO>
	<brief_summary>Objectives . To study short-term neurophysiological clinical outcome botulinum toxin type A ( BoNT-A ) , injected standard dos , ass toxin spread neighbor uninjected muscle child cerebral palsy . Subjects method . The investigator study 18 ambulatory child dynamic equinus foot deformity ( mean age 6.1 year ) . The gastrocnemius muscle affect side inject BoNT-A ( Dysport , range 8.9-19.4 U/kg ) . As primary neurophysiological outcome measure , compound muscle action potential ( CMAP ) area assess lateral gastrocnemius ( LG ) tibialis anterior ( TA ) muscle treat untreated side BoNT-A injection ( T0 ) , day 10 ( T10 ) , 30 ( T30 ) injection . Clinical scale assess video gait analyze three time point . Results . In patient , CMAP area record LG TA muscle treat side decrease significantly pre-injection value T10 ( p &lt; 0.05 ) T30 ( p &lt; 0.002 ) . Assessment time point injection also show ankle spasticity diminish ( p &lt; 0.05 ) , equinus foot excursion increase ( p &lt; 0.05 ) , functional gait improve ( p &lt; 0.05 ) . Conclusion . Although BoNT-A injected standard dose improve gait child spastic equinus foot toxin spread uninjected leg muscle . BoNT-A treatment cerebral palsy therefore need individualize accord child 's clinical feature .</brief_summary>
	<brief_title>Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>spasticity refractory oral medication patient able walk independently aid contraindication BoNTA treatment fixed contracture , aminoglycoside therapy myasthenia gravis neuromuscular disease orthopedic surgery normal mildly decline cognition previous treatment least six month study contraindication BoNTA treatment</criteria>
	<gender>All</gender>
	<minimum_age>25 Months</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>BoNT-A-botulinum neurotoxin type A</keyword>
	<keyword>CMAP-compound muscle action potential</keyword>
	<keyword>CP-cerebral palsy</keyword>
	<keyword>LG-lateral gastrocnemius</keyword>
	<keyword>MG-medial gastrocnemius</keyword>
	<keyword>TA-tibialis anterior</keyword>
	<keyword>PROMS-passive range movement</keyword>
	<keyword>MAS-modified Ashworth scale</keyword>
	<keyword>EVGS-Edinburgh visual gait scale</keyword>
	<keyword>GMF-CS-gross motor function classification system</keyword>
</DOC>